Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and the length of effect on platelet
build-up in the arteries of Durlaza™ as compared to immediate-release Bayer® aspirin 81 mg or
subject's current aspirin 81 mg of choice in patients who have Type 2 diabetes mellitus and
cardiovascular disease or multiple risk factors of developing cardiovascular disease.